TMO SEC Filings

Thermo Fisher Scientific Inc. (TMO) has announced the successful completion of a significant public offering of senior notes, raising approximately $3.76 billion in net proceeds. This capital infusion comprises four tranches of notes with varying interest rates and maturity dates, ranging from 2031 to 2046. The primary stated purpose of this offering is to fund a portion of the cash consideration for the previously announced acquisition of Clario Holdings, Inc., underscoring the company's strategic growth initiatives. While the acquisition of Clario is subject to customary closing conditions and regulatory approvals, TMO has outlined plans for the proceeds. Pending the acquisition's completion, a portion of the funds may be allocated to general corporate purposes, including potential future acquisitions, debt repayment, working capital, capital expenditures, or share repurchases. The notes are unsecured general obligations of the company and rank equally with existing unsecured and unsubordinated debt. The filing also details provisions related to early redemption, change of control scenarios, and standard covenants limiting certain secured debt and major asset dispositions.

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report on January 28, 2026, announcing its financial results for the fiscal quarter and year ended December 31, 2025. The press release containing these detailed results is furnished as an exhibit to this filing, providing investors with the latest performance data. This filing serves as the primary vehicle for investors to access TMO's fourth-quarter and full-year 2025 financial performance. While specific figures are not detailed within the 8-K itself, investors are directed to the furnished press release (Exhibit 99.1) for comprehensive insights into revenue, earnings, and other key financial metrics. This information is crucial for assessing the company's recent operational success and its trajectory heading into the next fiscal year.

Thermo Fisher Scientific Inc. (TMO) has announced significant changes to its executive leadership team through an 8-K filing. Two long-serving executives, Michel Lagarde (Executive Vice President and Chief Operating Officer) and Frederick M. Lowery (Executive Vice President), are departing to pursue other opportunities. Mr. Lagarde's last day will be March 31, 2026, and Mr. Lowery's will be February 28, 2026. These departures coincide with a planned organizational restructuring and leadership transition effective March 1, 2026. Marc N. Casper will assume the combined role of Chairman and Chief Executive Officer. Gianluca Pettiti is promoted to President and Chief Operating Officer, and Michael Shafer will move into an expanded role reporting directly to the CEO. Investors should monitor how these leadership changes and structural adjustments impact the company's strategic execution and operational efficiency in the coming quarters.

Thermo Fisher Scientific Inc. (TMO) announced the issuance of €1.0 billion in Floating Rate Senior Notes due 2027 and €1.1 billion in 3.628% Senior Notes due 2035 by its indirect wholly-owned finance subsidiary, Thermo Fisher Scientific (Finance I) B.V. The Company is fully and unconditionally guaranteeing these notes on a senior unsecured basis. This transaction represents a significant capital raise totaling approximately €2.1 billion in net proceeds after expenses. The proceeds from this offering are intended for general corporate purposes, including potential acquisitions, debt repayment, working capital needs, capital expenditures, or equity repurchases. The company may also temporarily invest these proceeds in short-term liquid investments. The issuance of these notes provides Thermo Fisher with substantial financial flexibility for strategic initiatives and operational needs.

Thermo Fisher Scientific Inc. (TMO) reported solid financial results for the nine months ended September 27, 2025, with total revenues increasing by 3% year-over-year to $32.34 billion. Net income attributable to Thermo Fisher Scientific Inc. grew to $4.74 billion, a 5.3% increase from the prior year period. The company demonstrated strong operational execution, reflected in an increase in both GAAP and adjusted operating income margins, driven by significant productivity improvements across its segments. The company continued its strategic growth initiatives, including targeted acquisitions. Notable acquisitions during the period include the Filtration and Separation business from Solventum Corporation and Olink Holding AB. Management also highlighted ongoing efforts to streamline operations through restructuring actions, primarily in the Laboratory Products and Biopharma Services segment. Despite some market headwinds, such as customer hesitancy in the academic and government sector and challenges in China's diagnostics and healthcare market, Thermo Fisher's diversified business model and strong execution in core markets like pharma and biotech have driven performance.

Thermo Fisher Scientific Inc. (TMO) announced on October 29, 2025, a significant strategic move: the execution of a definitive agreement to acquire Clario Holdings, Inc. for approximately $8.875 billion in cash. This transaction, which also includes deferred and contingent consideration, is a substantial investment aimed at bolstering Thermo Fisher's existing portfolio. The acquisition is anticipated to close by mid-2026, subject to customary closing conditions and regulatory approvals. This acquisition represents a major growth initiative for Thermo Fisher, indicating confidence in its strategic direction and market position. Investors should monitor the progress of regulatory approvals and the successful integration of Clario's business, as the realization of expected synergies and operational efficiencies will be key to justifying the acquisition's valuation. The company's disclosure highlights potential risks associated with the transaction, including integration challenges and the possibility that anticipated benefits may not materialize.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on October 22, 2025, to report its financial results for the fiscal quarter ended September 27, 2025. The key information is contained within the press release furnished as Exhibit 99.1, which provides details on the company's performance during the quarter. Investors should review this press release for specific financial metrics, operational updates, and forward-looking statements. While the 8-K itself is a notification filing, the accompanying press release (Exhibit 99.1) is the primary source of detailed financial information. This includes earnings per share, revenue figures, and potentially commentary on segment performance and guidance for future periods. The filing clarifies that the information is furnished and not deemed 'filed' for certain legal purposes, a standard disclosure for earnings releases included in 8-Ks.

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report announcing the issuance of a substantial amount of senior notes, totaling $2.5 billion, across four tranches with varying maturity dates and interest rates. This debt offering includes $500 million in 4.200% Senior Notes due 2031, $750 million in 4.473% Senior Notes due 2032, $750 million in 4.794% Senior Notes due 2035, and $500 million in 4.894% Senior Notes due 2037. The net proceeds from this offering are expected to be approximately $2.48 billion and are designated for general corporate purposes, including potential acquisitions, debt repayment, working capital, capital expenditures, or equity repurchases. From an investor's perspective, this filing signals Thermo Fisher's proactive approach to managing its capital structure and funding future growth initiatives. The diversification of maturity dates and interest rates suggests a strategic approach to debt management. While the notes are general unsecured obligations, they rank equally with existing and future unsecured and unsubordinated debt. Investors should note the covenants that restrict the company's ability to incur certain secured debt and engage in sale-leaseback transactions, as well as limitations on mergers and asset sales. The filing also outlines provisions for redemption by the company and a potential put option for noteholders in the event of a change of control coupled with a credit rating downgrade.

Thermo Fisher Scientific Inc. (TMO) announced on September 2, 2025, the successful completion of its acquisition of Solventum Corporation's purification and filtration business. This strategic move is expected to enhance Thermo Fisher's portfolio within the life sciences and diagnostics sectors, potentially driving future revenue growth and market share expansion. Investors should monitor the integration of this new business segment and its impact on the company's financial performance in upcoming quarters. The acquisition signifies Thermo Fisher's ongoing commitment to inorganic growth and its strategy of acquiring complementary businesses to strengthen its competitive position. While the immediate financial implications are not detailed in this 8-K filing, the press release (Exhibit 99.1) likely provides further context on the deal's rationale and expected synergies. Investors are encouraged to review the referenced press release for a more comprehensive understanding of this development.

Thermo Fisher Scientific Inc. reported solid revenue growth in the second quarter and first half of 2025, driven by strong performance in its Life Sciences Solutions and Laboratory Products and Biopharma Services segments. While overall revenue increased by 3% and 2% respectively for the periods, the company's profitability metrics showed some mixed signals. Operating income saw marginal increases, but operating income margins experienced slight declines, attributed to unfavorable business mix, strategic investments, and tariff impacts. The company also announced a significant pending acquisition of Solventum Corporation's Purification and Filtration business for approximately $4.0 billion, expected to close by year-end 2025, which will further bolster the Life Sciences Solutions segment. Despite a slight decrease in free cash flow compared to the prior year, driven by increased debt issuance and share repurchases, Thermo Fisher maintains a strong liquidity position and expects to meet its cash requirements. The company continues to execute its growth strategy focused on innovation, customer partnerships, and its commercial engine, while managing costs through productivity improvements and restructuring efforts. Investors should monitor the integration of recent and pending acquisitions and the ongoing impact of global economic conditions on customer spending, particularly in the Analytical Instruments segment.

Thermo Fisher Scientific Inc. (TMO) has announced a significant leadership transition within its finance department. Senior Vice President and Chief Financial Officer, Stephen Williamson, will retire effective March 31, 2026. This planned retirement marks the end of an era for the company's financial leadership, providing ample time for a smooth handover. Investors should note the timing of this transition, allowing for continuity in financial strategy and operations.

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report on July 23, 2025, to announce its financial results for the fiscal quarter ended June 28, 2025. This filing primarily serves to furnish the accompanying press release, which contains the detailed financial performance of the company for the period. Investors should refer to the press release (Exhibit 99.1) for specific figures related to revenue, profitability, and any forward-looking guidance issued by the company. The information provided in this 8-K is crucial for understanding TMO's operational performance in the second quarter of 2025. While the 8-K itself does not contain the financial statements, it directs investors to the press release for the results of operations and financial condition. Investors are advised to carefully review the press release for key metrics, segment performance, and management's commentary on the business environment and outlook.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on May 27, 2025, detailing the outcomes of its Annual Meeting of Shareholders held on May 21, 2025. The primary focus of the filing is the voting results on several key proposals. Notably, all nominated directors were overwhelmingly elected to the Board of Directors, indicating strong shareholder confidence in the current leadership and governance structure. However, a significant point for investors is the non-binding advisory vote on executive compensation, which was not approved by shareholders. This suggests a potential disconnect between shareholder expectations and the company's executive pay practices. Additionally, a shareholder proposal to remove the one-year holding period for calling a special meeting also failed to gain approval, maintaining the status quo on shareholder-initiated extraordinary actions. The ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025 received strong shareholder support.

Thermo Fisher Scientific Inc. announced a significant long-term incentive award to its Chairman, President, and CEO, Marc N. Casper. The company's Board of Directors approved a 5-year performance-based restricted stock unit (RSU) award with a target grant date fair value of approximately $60 million. This award is designed to incentivize continued leadership through at least May 2030 and to drive substantial shareholder returns, specifically through outperformance in Total Shareholder Return (TSR) relative to the S&P 500. The Board's decision was based on a thorough review, highlighting Mr. Casper's extensive track record of value creation, including quadrupling annual revenue to $43 billion and achieving over 800% TSR during his tenure, significantly outperforming the S&P 500 Equal Weight Index. Investor feedback also underscored the importance of his continued leadership for long-term value creation. The award structure, with a 5-year cliff vesting and an additional deferred share delivery for up to 10 years post-grant, aims to ensure sustained alignment with shareholder interests.

Thermo Fisher Scientific Inc. reported a modest increase in total revenues for the first quarter of 2025, reaching $10.36 billion, up slightly from $10.34 billion in the prior year period. This growth was driven by positive contributions from the Analytical Instruments, Specialty Diagnostics, and Life Sciences Solutions segments, partially offset by a decline in the Laboratory Products and Biopharma Services segment, influenced by the moderation of COVID-19 related revenues. The company demonstrated resilience with a 15% increase in GAAP diluted earnings per share to $3.98, while adjusted diluted EPS saw a 1% rise to $5.15. Key drivers for earnings improvement included strong productivity gains and a favorable tax benefit from a domestication transaction, which helped to offset unfavorable business mix and strategic investments. From a balance sheet perspective, total assets grew to $99.04 billion, supported by robust cash and cash equivalents of $4.13 billion. The company maintained a strong liquidity position, with no outstanding borrowings under its $5 billion revolving credit facility as of quarter-end. Thermo Fisher continued its capital deployment strategy, repurchasing $2.00 billion of its common stock and paying $0.15 billion in dividends during the quarter. The company also announced a significant pending acquisition of Solventum Corporation’s Purification & Filtration business for approximately $4.1 billion, expected to close by year-end 2025, which is poised to strengthen its Life Sciences Solutions segment.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on April 23, 2025, to announce its financial results for the fiscal quarter ended March 29, 2025. The company released its earnings and furnished the full press release as an exhibit to the filing. Investors should refer to the press release (Exhibit 99.1) for detailed financial performance, operational highlights, and forward-looking guidance for the first quarter of 2025. While the 8-K itself does not contain the specific financial figures, it serves as the official notification for the release of this crucial information. The furnished press release will contain key metrics such as revenue, earnings per share (EPS), and potentially segment performance, offering insights into the company's current financial health and outlook. Investors should consult the press release for a comprehensive understanding of TMO's Q1 2025 performance.

Thermo Fisher Scientific Inc. (TMO) announced a significant strategic acquisition on February 25, 2025, agreeing to purchase Solventum Corporation's purification and filtration business for approximately $4.1 billion in cash. This move is expected to bolster TMO's existing portfolio within its life sciences solutions segment. The transaction is anticipated to close by the end of 2025, subject to standard closing conditions and necessary regulatory approvals. Investors should monitor the progress of these approvals and the integration process, as the company has outlined potential risks and uncertainties, including the possibility that expected benefits and synergies may not materialize as anticipated or that the transaction may not be completed within the expected timeframe.

Thermo Fisher Scientific Inc. reported relatively flat revenue for the year ended December 31, 2024, compared to the previous year, with consolidated revenues of $42.88 billion. While GAAP operating income saw a 7% increase to $7.34 billion, adjusted operating income slightly decreased by 1% to $9.71 billion. Diluted earnings per share (EPS) on a GAAP basis increased by 7% to $16.53, while adjusted EPS grew by 1% to $21.86. The company experienced a significant decline in COVID-19 related sales, which impacted the Life Sciences Solutions segment with a 3% revenue decrease. However, growth in Analytical Instruments and Specialty Diagnostics, alongside a slight increase in Laboratory Products and Biopharma Services, helped offset these declines. Strategic investments in innovation and commercial capabilities were noted as drivers for growth in academic, government, industrial, and applied markets, despite a muted macroeconomic environment impacting most end markets and geographies.

Thermo Fisher Scientific Inc. (TMO) announced a strategic addition to its Board of Directors with the election of Karen S. Lynch, effective February 19, 2025. Ms. Lynch brings extensive experience in the healthcare sector, notably her tenure as former president and CEO of CVS Health, where she oversaw a vast employee base and significant consumer reach. Her appointment is expected to strengthen the Board's expertise, particularly as she is anticipated to serve on the Audit Committee.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on January 30, 2025, to announce its financial results for the fiscal quarter and full year ended December 31, 2024. The press release containing these detailed results is furnished as an exhibit to this filing, providing investors with key performance metrics and financial condition updates for the period. This report serves as the primary disclosure vehicle for the company's latest financial performance, enabling stakeholders to assess the company's recent operational success and outlook.

Thermo Fisher Scientific Inc. reported steady revenue performance for the third quarter of fiscal year 2024, with total revenues reaching $10.598 billion, largely in line with the prior year's $10.574 billion. For the nine-month period, revenues saw a slight decrease of 2% to $31.484 billion from $31.971 billion in the prior year. The company experienced a year-over-year decrease in diluted EPS for the quarter to $4.25 from $4.42, but a growth in diluted EPS for the nine-month period to $11.75 from $11.25. This performance reflects a normalization of COVID-19 related demand and a challenging macroeconomic environment impacting revenue growth across several segments, particularly Life Sciences Solutions and Laboratory Products and Biopharma Services. The company continues to strategically invest in innovation and commercial capabilities. The acquisition of Olink Holding AB in July 2024 for $3.146 billion, focused on enhancing its proteomics capabilities within the Life Sciences Solutions segment, is a key strategic move. Despite revenue headwinds from declining COVID-19 related demand, the company is demonstrating operational resilience with strong productivity improvements and cost management, as evidenced by the growth in GAAP operating income for the nine-month period and a solid operating margin. Management remains confident in its ability to meet future cash requirements through existing cash, operating cash flow, and available credit, while continuing to return capital to shareholders through share repurchases and dividends.

Thermo Fisher Scientific Inc. (TMO) has filed a Form 8-K to announce its financial results for the fiscal quarter ended September 28, 2024. The press release detailing these results, furnished as Exhibit 99.1, is the primary piece of new information for investors in this filing. This report serves as the official notification of the company's performance during the third quarter of its fiscal year.

Thermo Fisher Scientific Inc. (TMO) reported its second-quarter and first-half 2024 results, demonstrating resilience amidst a moderating macroeconomic environment. Total revenues saw a slight decline year-over-year for both periods, primarily due to a decrease in COVID-19 related product demand. However, the company continues to show strong operational execution with an increase in GAAP operating income and margin, driven by productivity improvements and a favorable business mix, partially offset by lower restructuring charges compared to the prior year. Adjusted operating income and margin remained stable, highlighting the company's consistent performance. The company also announced the significant acquisition of Olink Holding AB, a move aimed at bolstering its Life Sciences Solutions segment in the high-growth proteomics market. This strategic acquisition, along with ongoing focus on innovation and customer partnerships, positions Thermo Fisher for future growth. Despite the revenue headwinds from declining COVID-19 related sales, the company's strong cash flow generation and robust balance sheet provide confidence in its ability to navigate current market conditions and pursue strategic growth initiatives.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on July 24, 2024, primarily to announce its financial results for the fiscal quarter ended June 29, 2024. The press release containing these results is furnished as Exhibit 99.1, and investors should refer to this document for detailed financial performance and operational updates for the quarter. This filing serves as the official notification of the company's latest financial performance, crucial for understanding its current business trajectory and for making informed investment decisions. While the 8-K itself is brief and mainly points to the attached press release, the underlying financial results will shed light on key performance indicators such as revenue, earnings per share (EPS), and segment performance. Investors will be looking for updates on growth drivers, any forward-looking guidance provided by management, and the company's ability to navigate the current economic environment. The furnished press release is the primary source for all material financial and operational information related to the second quarter of 2024.

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report on July 10, 2024, detailing the expiration and results of a tender offer conducted by its wholly owned subsidiary, Orion Acquisition AB. The tender offer aimed to acquire all outstanding common shares and American Depositary Receipts (ADRs) of Olink Holding AB (publ). This event signifies a major step towards Thermo Fisher's potential acquisition of Olink, a development that could have significant strategic and financial implications for the company and its shareholders.

This 8-K filing from Thermo Fisher Scientific Inc. reports the outcomes of their Annual Meeting of Shareholders held on May 22, 2024. The primary focus is on the voting results for several key proposals. All incumbent directors were overwhelmingly re-elected to the Board, indicating strong shareholder confidence in the current leadership and governance. Additionally, shareholders approved the executive compensation plan on a non-binding advisory basis, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the upcoming fiscal year.

Thermo Fisher Scientific Inc. (TMO) reported its first-quarter 2024 financial results, showing total revenues of $10.35 billion, a decrease of 3% compared to the prior year's $10.71 billion. This decline was primarily driven by a decrease in Life Sciences Solutions and Analytical Instruments segments, partly offset by stable performance in Specialty Diagnostics and Laboratory Products and Biopharma Services. Despite the revenue dip, operating income saw a modest 6% increase to $1.66 billion, leading to diluted earnings per share (EPS) of $3.46, up from $3.32 in the first quarter of 2023. The company continues to navigate a complex market, with a decrease in COVID-19 related revenue impacting performance. However, management highlights strong productivity improvements and strategic investments as key drivers for future growth. The company also announced its intent to acquire Olink Holding AB for approximately $3.1 billion, expected to close mid-year 2024, which is anticipated to enhance its proteomics capabilities.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on April 24, 2024, to announce its financial results for the fiscal quarter ended March 30, 2024. This filing primarily consists of furnishing the company's earnings press release as an exhibit. Investors should refer to Exhibit 99.1 for detailed financial performance, including revenue, earnings per share, and segment-specific results for the first quarter of 2024. While the 8-K itself is brief, it signals that the company has publicly disclosed its latest financial performance. Key metrics and management's commentary on future outlook and business drivers will be found within the accompanying press release. Investors are advised to review this document to understand TMO's operational performance and financial health as of the end of Q1 2024.

Thermo Fisher Scientific Inc. reported a 5% decrease in revenue for the fiscal year ended December 30, 2023, primarily driven by a significant decline in COVID-19 related sales, which fell from $3.11 billion in 2022 to $0.33 billion in 2023. This reduction was partially offset by strong performance in the Analytical Instruments segment and the Laboratory Products and Biopharma Services segment, which saw revenue increases of 10% and 2% respectively on an organic basis. The company also executed significant restructuring actions, incurring $0.2 billion in charges to streamline operations, which are expected to yield $0.5 billion in annual cost savings. The company continues to focus on its three-pillar growth strategy: high-impact innovation, trusted partner status with customers, and an unparalleled commercial engine. Strategic acquisitions in 2023 included The Binding Site Group for specialty diagnostics and CorEvitas, LLC for real-world evidence solutions. Thermo Fisher also announced a proposed acquisition of Olink Holding AB for approximately $3.1 billion to expand its proteomics capabilities, subject to regulatory approvals and tender offer completion. Despite the revenue decline, the company maintained a strong free cash flow of $7.014 billion and returned capital to shareholders through share repurchases totaling $3.00 billion and dividend payments. The company ended the year with a robust cash position of $8.077 billion.

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report on January 31, 2024, to announce its financial results for the fiscal quarter and full year ended December 31, 2023. The key details of these results are provided in a press release furnished as Exhibit 99.1 to this filing. Investors should review this press release for specific figures related to revenue, earnings, and other financial performance indicators. While this 8-K filing itself is primarily a notification of the earnings release, it directs investors to the accompanying press release for comprehensive financial data. This includes information on the company's operational performance, financial condition, and likely forward-looking statements or guidance. Investors are advised to access Exhibit 99.1 for a detailed understanding of TMO's performance during the reported periods and any implications for future financial trends.

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report detailing a significant debt issuance. On December 5, 2023, the company successfully raised approximately $2.5 billion in aggregate principal amount through the public offering of senior notes across three tranches: $1 billion of 5.000% Senior Notes due 2026, $1 billion of 5.000% Senior Notes due 2029, and $500 million of 5.200% Senior Notes due 2034. These notes are general unsecured obligations, ranking equally with existing unsecured debt and senior to subordinated debt, but are effectively subordinated to secured debt and structurally subordinated to subsidiary debt. The net proceeds from this offering are earmarked for general corporate purposes. This can include strategic initiatives such as acquisitions, debt repayment or refinancing, working capital needs, capital expenditures, or equity repurchases. The company may also temporarily invest the proceeds in liquid investments until their intended use. The issuance, governed by a base indenture and a supplemental indenture, includes standard provisions for redemption, a change of control offer to purchase, and limited negative covenants that restrict the incurrence of secured debt and sale-leaseback transactions involving principal properties, as well as limits on mergers and asset sales.

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report to announce a temporary suspension of trading under its 401(k) plan, commonly known as a "blackout period." This suspension is necessary to facilitate the transition to a new plan administrator for the 401(k) plan. The blackout period is scheduled to begin on December 21, 2023, and is expected to conclude during the week of January 14, 2024. During this time, participants will be unable to make transactions such as contribution changes, investment allocations, loan requests, or withdrawals.

Thermo Fisher Scientific Inc. reported total revenues of $10.57 billion for the third quarter of 2023, a slight decrease of 1% year-over-year, and $31.97 billion for the first nine months, down 4%. This decline is largely attributable to the significant reduction in COVID-19 related product demand, which impacted the Life Sciences Solutions and Specialty Diagnostics segments most notably. Despite the revenue headwinds, the company demonstrated strong operational execution, with adjusted operating income increasing by 8% year-over-year for the quarter, driven by robust productivity improvements and effective price realization. This points to the resilience of its core business and its ability to manage costs effectively amidst a challenging macroeconomic environment. The company continues to focus on strategic growth through innovation, its partner status with customers, and its commercial engine. A significant development during the quarter was the proposed acquisition of Olink Holding AB for approximately $3.1 billion, which is expected to close by mid-year 2024 and will enhance its capabilities in next-generation proteomics. This strategic acquisition, alongside ongoing investments in R&D and operational efficiencies, underscores Thermo Fisher's commitment to long-term growth and market leadership in the life sciences and diagnostics sectors.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on October 25, 2023, to announce its financial results for the fiscal quarter ended September 30, 2023. The press release containing these results, furnished as Exhibit 99.1, is the primary focus of this filing, providing investors with key performance indicators and financial condition details for the period. Investors should review the furnished press release for specific figures related to revenue, earnings, and any forward-looking statements or guidance provided by the company. This filing serves as the official communication channel for TMO's third-quarter performance. While the 8-K itself is brief, it directs stakeholders to the comprehensive press release for the substantive financial information. This includes insights into the company's operational performance, segment results, and overall financial health, which are crucial for assessing the company's trajectory and investment potential.

Thermo Fisher Scientific Inc. announced on October 17, 2023, that it has entered into a Purchase Agreement with Olink Holding AB (publ) to commence a tender offer for all outstanding common shares and American Depositary Shares of Olink. This strategic move signifies Thermo Fisher's intent to acquire Olink, a company specializing in advanced protein biomarker detection. Investors should note that the tender offer has not yet commenced, and the announcement serves as informational, not an offer to purchase. The acquisition, if successful, is expected to expand Thermo Fisher's capabilities in life sciences research and diagnostics. The filing also includes standard forward-looking statements and details on where investors can find additional information regarding the tender offer as it progresses through regulatory filings. The deal is subject to customary closing conditions and regulatory approvals.

Thermo Fisher Scientific Inc. (TMO) has filed an amendment to its previously submitted Current Report on Form 8-K, clarifying the committee assignments for a newly elected director. The amendment, filed on September 21, 2023, confirms that Jennifer "Jenny" Johnson, who was elected to the Board of Directors on July 13, 2023, has now been appointed to the Audit Committee. This appointment is effective as of September 21, 2023. While this filing primarily addresses a procedural update regarding committee appointments, it is important for investors to note that Ms. Johnson's role on the Audit Committee provides oversight of the company's financial reporting and internal controls. Investors often view committee assignments, particularly to the Audit Committee, as a key indicator of a director's responsibilities and the company's commitment to robust financial governance.

Thermo Fisher Scientific Inc. (TMO) has announced a significant debt offering, issuing a total of $2.95 billion in aggregate principal amount of Senior Notes across four tranches with varying maturity dates and interest rates. These notes include $600 million of 4.953% Senior Notes due 2026, $750 million of 4.977% Senior Notes due 2030, $1 billion of 5.086% Senior Notes due 2033, and $600 million of 5.404% Senior Notes due 2043. The company has also entered into cross-currency swaps totaling $2.95 billion. The primary stated use of the net proceeds, estimated at approximately $2.92 billion after expenses, is to redeem outstanding Floating Rate Senior Notes maturing in October 2023 and October 2024, totaling $1 billion. The remaining proceeds are earmarked for general corporate purposes, which may include acquisitions, debt repayment, working capital, capital expenditures, equity repurchases, or temporary investments. The issuance of these new notes adds to the company's long-term debt structure and is governed by an indenture with standard covenants related to liens, sale and lease-back transactions, and mergers or consolidations.

Thermo Fisher Scientific Inc. (TMO) has announced significant debt management activities through an 8-K filing dated August 8, 2023. The company is initiating the redemption of its $1.0 billion aggregate principal amount of Floating Rate Senior Notes due 2023 and 2024. This redemption is scheduled to occur on August 18, 2023, with the notes being repurchased at par value plus accrued interest. To finance this debt retirement, Thermo Fisher successfully priced a substantial new debt offering totaling $2.75 billion across multiple tranches with varying maturity dates and fixed interest rates. The company intends to utilize the proceeds from this new offering to fund the upcoming redemption. This strategic move suggests a proactive approach to optimizing the company's capital structure by replacing floating-rate debt with fixed-rate obligations, potentially locking in lower interest costs and enhancing financial predictability.

Thermo Fisher Scientific Inc. (TMO) reported revenues of $10.7 billion for the third quarter of 2023, a slight decrease of 3% year-over-year, impacted by the ongoing decline in COVID-19 related sales and a challenging macroeconomic environment. Despite the revenue dip, the company demonstrated resilience through strong execution of its growth strategy and productivity improvements. For the six-month period, revenues were $21.4 billion, down 6% year-over-year, also heavily influenced by the normalization of COVID-19 demand. The company's operational performance was marked by a 21% decrease in GAAP operating income to $1.6 billion for the quarter, and a 35% decrease to $3.1 billion for the six-month period, largely due to lower COVID-19 related revenues and increased strategic growth investments. However, adjusted operating income, which excludes certain items, showed a more moderate decline, reflecting the underlying operational strength. The balance sheet remains robust, although cash and cash equivalents decreased significantly to $3.1 billion from $8.5 billion, primarily due to significant capital deployment activities including acquisitions and share repurchases.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on July 26, 2023, to report its financial results for the fiscal quarter ended July 1, 2023. The key information for investors is contained within the press release furnished as Exhibit 99.1 to this filing, which provides details on the company's performance and financial condition for the period. While the 8-K itself is a procedural document notifying the market of the earnings release, investors should refer to the attached press release for specifics on revenue, earnings per share (EPS), segment performance, and forward-looking guidance. This filing serves as the official notification of these results, making the press release the primary source for detailed financial analysis.

Thermo Fisher Scientific Inc. (TMO) announced a change to its Board of Directors. Effective July 13, 2023, the Board's size was increased to twelve members with the appointment of Jennifer “Jenny” Johnson as a new director. Ms. Johnson brings extensive leadership experience, currently serving as President and CEO of Franklin Resources, Inc., a global asset manager with over $1.4 trillion in assets under management, and has a 35-year career at the company. Her appointment is expected to add valuable insights to Thermo Fisher's board, given her deep experience across various facets of a large financial services organization. Ms. Johnson will serve a term expiring at the Company's 2024 annual meeting and will be compensated according to the company's standard arrangements for non-employee directors. The board has not yet assigned her to any committees.

This 8-K filing from Thermo Fisher Scientific (TMO) reports on the outcomes of its annual shareholder meeting held on May 24, 2023. The most significant investor-focused information pertains to the approval of key equity incentive plans and the composition of the Board of Directors. Shareholders overwhelmingly approved the Amended and Restated 2013 Stock Incentive Plan, which includes an increase in the number of authorized shares, and the 2023 Global Employee Stock Purchase Plan. These approvals are crucial for the company's ability to attract and retain talent through equity-based compensation and to allow employee participation in stock ownership. Additionally, all incumbent directors seeking re-election were overwhelmingly approved for another one-year term, indicating strong shareholder confidence in the current leadership and governance. The compensation of named executive officers was also approved on an advisory basis, as was the frequency of such votes (annually). The ratification of PricewaterhouseCoopers LLP as the independent auditor further signifies routine corporate governance and financial oversight activities. These events are primarily housekeeping items related to long-term incentive structures and board oversight, generally viewed positively by investors as they support management's ability to incentivize and retain key personnel and maintain established governance practices.

Thermo Fisher Scientific Inc. reported first quarter 2023 revenues of $10.71 billion, a decrease of 9% year-over-year, primarily driven by a significant decline in COVID-19 related revenue. Despite the top-line decrease, the company demonstrated resilience with adjusted operating income of $2.33 billion and adjusted EPS of $5.03, reflecting strong pricing and productivity measures. The company also continues to execute its growth strategy, including strategic investments and a notable acquisition of The Binding Site Group in January 2023 for $2.7 billion, which is expected to bolster its Specialty Diagnostics segment. Cash flow from operations was $729 million, though free cash flow saw a substantial decrease to $277 million compared to $1.56 billion in the prior year period, largely due to higher investments in working capital and acquisitions. The company maintained a strong balance sheet with approximately $3.5 billion in cash and equivalents and continued its commitment to shareholders through share repurchases totaling $3.0 billion in the quarter, while maintaining its credit facility capacity. Management remains confident in the company's ability to meet its financial obligations and fund its ongoing operations and strategic initiatives.

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report on April 26, 2023, to announce its financial results for the fiscal quarter ended April 1, 2023. This filing primarily serves to furnish the press release detailing these results, which is incorporated by reference. Investors should refer to the press release (Exhibit 99.1) for the specific financial performance, including revenue, earnings per share, and any segment-specific details for the reported quarter. While the 8-K itself does not contain the detailed financial figures, it formally disseminates the official earnings announcement. The content of the press release will provide insights into the company's operational performance, its financial condition, and potentially any forward-looking statements or guidance provided by management. Investors are encouraged to review this press release thoroughly to understand the company's recent performance and future outlook.

Thermo Fisher Scientific Inc. reported strong revenue growth of 15% for the fiscal year ended December 30, 2022, reaching $44.9 billion. However, GAAP operating income and diluted EPS saw a decline of 16% and 9% respectively, year-over-year, largely due to reduced COVID-19 testing volumes and strategic growth investments. The company's organic revenue growth was flat (0%) for the year, indicating a normalization after significant pandemic-related demand. The Life Sciences Solutions and Specialty Diagnostics segments experienced revenue declines, primarily driven by decreased demand for COVID-19 related products. Conversely, the Analytical Instruments and Laboratory Products and Biopharma Services segments demonstrated robust growth. The company continues to execute its three-pillar growth strategy: developing innovative products, leveraging scale in high-growth markets, and delivering a unique value proposition. Despite the headwinds from lower COVID-19 demand, Thermo Fisher maintains a strong financial position with robust free cash flow generation of $6.9 billion. The company also remains committed to capital allocation through share repurchases and dividends, with $1 billion authorized for future repurchases as of February 23, 2023.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on February 1, 2023, to announce its financial results for the fourth quarter and full fiscal year ended December 31, 2022. The core of this filing is the accompanying press release (Exhibit 99.1), which provides detailed operational and financial performance metrics that investors will scrutinize to assess the company's recent trajectory and future outlook. While the 8-K itself is a notification of the release of these results, the investor focus will be on the content of the press release. Key areas to examine include revenue growth, profitability, earnings per share (EPS), and any forward-looking guidance provided by the company. These figures will offer insights into how TMO navigated the macroeconomic environment in late 2022 and its expectations for the upcoming fiscal year, influencing investor sentiment and stock valuation.

Thermo Fisher Scientific Inc. (TMO) announced on November 21, 2022, the completion of a significant debt financing initiative, raising a total of €1.25 billion and $1.2 billion through public offerings of senior notes. The Euro offering comprised €500 million of 3.200% Senior Notes due 2026 and €750 million of 3.650% Senior Notes due 2034. Concurrently, the USD offering included $600 million of 4.800% Senior Notes due 2027 and $600 million of 4.950% Senior Notes due 2032. The company intends to utilize the net proceeds, totaling approximately €1.24 billion from the Euro offering and $1.19 billion from the USD offering, for general corporate purposes. These purposes may encompass acquisitions, debt repayment, working capital needs, capital expenditures, or share repurchases. The company may also temporarily invest these proceeds in liquid short-term investments.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on November 14, 2022, to report an amendment to the equity compensation agreements for its CEO, Marc N. Casper. The amendment specifically addresses the retirement vesting provisions for Mr. Casper's equity awards, aligning them with those provided to all other officers of the company. This change was approved by the Compensation Committee of the Board of Directors on November 10, 2022. The company's Compensation Committee determined that this alignment is in the best interests of both Thermo Fisher Scientific and its stockholders. While the filing does not disclose specific financial figures related to this amendment, it signifies a move towards consistent executive compensation practices, particularly concerning retirement benefits for equity awards. Investors can find the full details of this agreement referenced as Exhibit 10.1 to the filing.

Thermo Fisher Scientific Inc. reported solid revenue growth in the third quarter and first nine months of 2022, driven by strong performance in North America and Asia Pacific, and across its Laboratory Products and Biopharma Services and Analytical Instruments segments. However, overall revenue growth was tempered by a significant decline in COVID-19 testing demand, particularly impacting the Life Sciences Solutions and Specialty Diagnostics segments. Despite the revenue headwinds and increased strategic investments, the company demonstrated resilience through effective pricing strategies and productivity improvements, though operating margins saw a decrease compared to the prior year. The company continues to focus on its three-pillar growth strategy: innovation, leveraging scale in emerging markets, and delivering unique customer value. A notable strategic move during the period was the agreement to acquire The Binding Site Group for £2.25 billion, which is expected to enhance its Specialty Diagnostics segment. The company also managed its capital effectively, with substantial cash flow from operations and a focus on strategic acquisitions, share buybacks, and dividends, while maintaining a strong liquidity position.

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on October 26, 2022, to announce its financial results for the fiscal quarter ended October 1, 2022. The press release containing these results is furnished as an exhibit. This filing provides investors with an update on the company's performance during the third quarter of fiscal year 2022. While the 8-K itself does not contain detailed financial figures, it directs investors to the accompanying press release (Exhibit 99.1) for comprehensive information. Investors should refer to this press release for key metrics such as revenue, earnings per share (EPS), and any forward-looking guidance provided by the company. This is a standard practice for 8-K filings related to earnings announcements, allowing for immediate dissemination of financial performance data.